在患有局部晚期胃癌,对新辅助化疗有不良病理反应的患者进行术后化疗放射治疗
Omer Gal1, Ron Lewin2, Gali Perl1
1Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.
Journal of cancer research and therapeutics
|March 30, 2024
概括
在局部晚期胃癌 (LAGC) 患者的术后化疗放射治疗 (CRT) 对新辅助化疗 (ChT) 反应不佳的患者显示出有希望的生存结果. 这种方法可能为选定的LAGC患者提供可行的治疗选择.
科学领域:
- 胃肠道瘤学 胃肠道瘤学
- 手术瘤学手术瘤学
- 辐射瘤学 辐射瘤学
背景情况:
- 局部晚期胃癌 (LAGC) 存在重大治疗挑战.
- 术后的新辅助化疗 (ChT) 是一种标准的方法.
- 识别对新辅助性CHT反应不佳的患者对于治疗适应至关重要.
研究的目的:
- 评估术后化疗放射治疗 (CRT) 在LAGC患者的疗效,这些患者对新辅助性ChT反应不佳.
- 评估这一特定患者群体的生存结果和术后CRT的耐受性.
主要方法:
- 对26名LAGC患者进行了回顾性审查,这些患者接受了外科手术和外科手术 (2009-2020年).
- 被选中的患者在新辅助性ChT后具有不良的病理原发性瘤反应 (ypT3-4,ypN2-3,R1切除).
- 手术后的CRT涉及45 Gy与capecitabine或5-fluorouracil. 这是一个非常好的方法.
主要成果:
- 在58%的患者中实现了R0切除.
- 随访时间中位数为39个月,54%的人出现了复发 (11远程,3局部区域).
- 中位数无进展生存期为23个月;中位数整体生存期为65个月.
- 估计的5年生存率为42% (PFS) 和54% (OS).
结论:
- 在LAGC患者中,术后的CRT对新辅助性ChT反应不佳,与历史对照相比,可能会产生有利的结果.
- 这种治疗一般都能很好地忍受.
- 基于新辅助剂反应的LAGC定制,适应性治疗策略的进一步研究是有必要的.
更多相关视频
03:32Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
Published on: December 27, 2024
683
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
162
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200